Targeting dysfunctional mitochondria in macrophages to inhibit atherosclerosis

针对巨噬细胞中功能失调的线粒体来抑制动脉粥样硬化

• 批准号: nhmrc : 1142938
• 负责人: A/Pr Andrew Murphy
• 金额: $ 68.28万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-dysfunctional-mitochondria-inhibit-atherosclerosis/1319821
• 关键词: Targeting; dysfunctional; mitochondria; macrophages; inhibit

The major contributing cells to heart disease are macrophages. These cells scavenge cholesterol, keeping the blood vessels clean and limiting heart disease. The macrophages must process and donate the scavenged cholesterol onto HDL-cholesterol that carries them back to the liver for removal. This process requires the powerhouse of the cell, the mitochondria to be functional. We have discovered that process fails and have novel drugs to re-instate this process of cholesterol removal.

导致心脏病的主要细胞是巨噬细胞。这些细胞分解胆固醇，保持血管清洁，限制心脏病。巨噬细胞必须处理并将清除的胆固醇捐赠给HDL-胆固醇，HDL-胆固醇将它们带回肝脏进行清除。这一过程需要细胞的发电站--线粒体发挥作用。我们已经发现这个过程失败了，并且有新的药物来恢复这个胆固醇去除过程。